Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:842-857.

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 A No. at risk T T T

Advertisements

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Trial Identification, Inclusion, and Exclusion Krista M. Dale et al, JAMA. 2006; 295:

ESH 2004 Paris1 Blood Pressure Control by Home Monitoring A Meta-Analysis of Randomised Trials FP Cappuccio, SM Kerry, L Forbes, A Donald Published in:

Information Resources for Evidence-Based Medicine A Review 3 rd Year Family Medicine Clerkship - EBM.

Edgar R. Miller III et al. Ann Intern Med. 2005; 142 Clinical Trials of Vitamin E Supplementation and Risk for All-Cause Mortality, Ordered by Dosage of.

CONSORT: Consolidated Standards of Reporting Trials Evidence-based, minimum set of recommendations for reporting clinical trials Rennie (JAMA) urged the.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Flow diagram of the systematic literature search indicating the inclusion and exclusion process of studies Liakopoulos OJ, et al. Eur Heart J 2008;29:

Slide Source Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Flow diagram of study selection process CAB: Commonwealth Agricultural Bureau Ethan M. Balk, et al. Arch Intern Med. 2007;167:21-30.

Process of study selection F. Sofi, et al. BMJ 2008 Sep 11;337:a1344.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Beaver Dam Eye Study: Overall Participant Flow Barbara E. K. Klein, et al. JAMA 2006;295:

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Copyright © 2012 American Medical Association. All rights reserved.

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

Surveillance. Public Health Approach Surveillance What is the Problem ? Problem Risk Factor Identification : What Is the Cause ? Intervention Evaluation.

(CMR vs. guidelines, p < 0.001)

Nurses' Health Study: Risk of hypertension associated with >1000 µg/day of folate vs

IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.

دانشیار دانشکده دندانپزشکی دانشگاه علوم پزشکی شهید صدوقی یزد

Fan et al. Am J Nephrol 2017;45: (DOI: / )

الأستاذ المساعد بقسم المناهج وطرق التدريس

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

CANOA Trial design: Patients undergoing percutaneous closure of an ASD with the Amplatzer Septal Occluder were randomized to aspirin 80 mg plus clopidogrel.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Relative risk of major events with atenolol vs placebo

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

Jun M, et al. Lancet 2010 Epub May 10

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.

Trial Selection Process

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Enrollment and Outcomes

Patient characteristics: American vs Canadian transplant patients

Literature Flow to Assess the Effects of Omega-3 Fatty Acid on Tumor Incidence Catherine H. MacLean, et al, JAMA. 2006; 295:

Berger JS, et al. JAMA 2009;301:

Flow of Patients Through Trial

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Study Participant Flow

Flow Diagram of the Trial Selection Process

by Kaiwen Chen, Matthew P. Cheng, Sarah P

Baseline Characteristics of the Study Participants

Baseline Characteristics

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

CAPP2: Time to first colorectal cancer in those randomized to aspirin compared with those randomized to the aspirin placebo. CAPP2: Time to first colorectal.

Patient flow and outcome in the overtreatment trial

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Flow diagram illustrating diabetes outcomes in the randomly assigned treatment of folic acid and vitamins B6 and B12 of the WAFACS. A total of 1,190 participants.

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

David J.A. Jenkins et al. JACC 2018;71:

Flow diagram of practices and participants

Standard Protocol Items: Recommendations for Interventional Trials diagram. Standard Protocol Items: Recommendations for Interventional Trials diagram.

Flow of recruitment: the screening and enrolment process for a 6-week randomised double-blind placebo-controlled feasibility trial in people with multiple.

Presentation transcript:

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Characteristics of Included Trials With High Risk of Bias Goran Bjelakovic, et al. JAMA. 2007;297:

Characteristics of Included Trials With Low Risk of Bias – Part I Goran Bjelakovic, et al. JAMA. 2007;297:

Characteristics of Included Trials With Low Risk of Bias – Part II Goran Bjelakovic, et al. JAMA. 2007;297:

Participants and Outcome Measures of Included Trials With High Risk of Bias Goran Bjelakovic, et al. JAMA. 2007;297:

Participants and Outcome Measures of Included Trials With Low Risk of Bias P.I Goran Bjelakovic, et al. JAMA. 2007;297:

Participants and Outcome Measures of Included Trials With Low Risk of Bias P.II Goran Bjelakovic, et al. JAMA. 2007;297:

Intervention Effect of Antioxidant Supplements vs Placebo on Mortality in Trials With Low Risk of Bias Goran Bjelakovic, et al. JAMA. 2007;297: